Nymox Pharma (NYMX) PR is a Repeat of Same Talking Points - Feuerstein
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
$NYMX issues new PR this morning which just repeats the same misleading, erroneous talking points about failed fexapotide clinical trials.— Adam Feuerstein (@adamfeuerstein) August 29, 2016
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA Advises Patients With St. Jude Medical (STJ) Heart Implants to Continue Using Devices - Reuters
- UPDATE: Cvent, Inc. (CVT) Active on Reports of DOJ Probe into Deal
- Stocks with call price movement; LC TWTR
Create E-mail Alert Related CategoriesFDA, Short Sales, Trader Talk
Related EntitiesAdam Feuerstein
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!